Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELSA-FN: Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
NCT04948463Phase 4Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Nov 2021
- Primary completion
- Dec 2025
- Modality
- Reversible Covalent Inhibitors, Cyclic Peptides, Antimicrobial Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of piperacillin + tazobactam, cefepime, ceftazidime, vancomycin, amikacin in febrile neutropenia (FN), sponsored by Murdoch Children's Research Institute. Started Nov 2021; status: completed.
02
Drugs
piperacillin + tazobactamcefepimeceftazidimevancomycinamikacin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT04948463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948463.